semaglutide and cardiovascular outcomes in obesity without diabetes journal club #VisualAbstract: Semaglutide and Cardiovascular Outcomes
Description
Journal of Pharmacology and Experimental Therapeutics, 2002, 302(3): 881-888
Our Mandeville providers oversee your monthly progress, adjusting dosages to sustain gradual and healthy weight loss
10.1016/j.orcp.2024.02.004 77
For semaglutide, while the core patent (protecting the molecule itself) expires in 2026, Novo Nordisk has likely filed secondary patents on aspects like formulations, dosage regimens, or delivery mechanismspotentially extending protection into the 2030s
